NCT05505253

Brief Summary

This is a study performed to evaluate the role of vitamin D supplementation on the strength of levator ani muscle in menopausal women with pelvic organ prolapse

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Nov 2020

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 15, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 17, 2022

Completed
Last Updated

August 17, 2022

Status Verified

August 1, 2022

Enrollment Period

12 months

First QC Date

August 15, 2022

Last Update Submit

August 15, 2022

Conditions

Keywords

AlfacalcidolMyoD expressionpelvic organ prolapsevitamin D receptorrlevator ani muscle strength

Outcome Measures

Primary Outcomes (3)

  • Vitamin D3 levels

    Vitamin D3 levels measured using lab tests

    3 months

  • Vitamin D receptor levels

    Vitamin D receptor levels as assessed by ELISA

    3 months

  • Levator ani muscle strength

    Levator ani muscle strength as measured using anometry

    3 months

Study Arms (2)

Alfacalcidol

ACTIVE COMPARATOR

Alfacalcidol 0.5 mcg orally given for 3 months

Drug: Alfacalcidol 0.0005 MG

Control

PLACEBO COMPARATOR

Placebo given orally for 3 months

Drug: Placebo

Interventions

Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured

Alfacalcidol

Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured

Control

Eligibility Criteria

Age40 Years - 75 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with pelvic organ prolapse stages III and IV who underwent surgery at menopausal age
  • normal BMI
  • initial serum vitamin D levels \<30 ng/mL

You may not qualify if:

  • comorbidities (chronic cough, conspitation)
  • vitamin D metabolism or immune system interfering diseases or drugs specific routine medications such as anticonvulsants, statin, fibrate or orlistat
  • history of vitamin D supplementation within the last month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universitas Padjadjaran

Bandung, West Java, 40161, Indonesia

Location

Related Publications (2)

  • Zhang L, Quan M, Cao ZB. Effect of vitamin D supplementation on upper and lower limb muscle strength and muscle power in athletes: A meta-analysis. PLoS One. 2019 Apr 30;14(4):e0215826. doi: 10.1371/journal.pone.0215826. eCollection 2019.

  • Latham CM, Brightwell CR, Keeble AR, Munson BD, Thomas NT, Zagzoog AM, Fry CS, Fry JL. Vitamin D Promotes Skeletal Muscle Regeneration and Mitochondrial Health. Front Physiol. 2021 Apr 14;12:660498. doi: 10.3389/fphys.2021.660498. eCollection 2021.

MeSH Terms

Conditions

Pelvic Organ Prolapse

Interventions

alfacalcidol

Condition Hierarchy (Ancestors)

ProlapsePathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • RM Sonny Sasotya, Ph.D.

    Universitas Padjadjaran

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 15, 2022

First Posted

August 17, 2022

Study Start

November 1, 2020

Primary Completion

October 31, 2021

Study Completion

December 31, 2021

Last Updated

August 17, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will share

Anonymised patient data are available upon written request to the authors

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
until 31 December 2026
Access Criteria
Access will be given upon written request to the authorrs

Locations